Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 08, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Following Positive Communication with the FDA, Regulatory Pathway Clarified for D-PLEX100 for Prevention of Abdominal Colorectal Surgical Site Infections Company Expects to Resume Patient...
January 31, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023

PETACH TIKVA, Israel, Jan. 31, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
January 24, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

• Regulatory Pathway for a Potential NDA Submission Clarified Following Recent Interactions with the FDA • FDA Acknowledged that SHIELD I Pre-specified Subgroup Results May Provide Supportive...
January 03, 2023 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery

D-PLEX100 Achieved in Phase 2 Trial Significant Reduction in SSIs in Patients with Multiple Preoperative Risk Factors Versus Standard of Care Results Consistent with SHIELD I Phase 3 Post-hoc...
December 12, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Scheduling of Type D Meeting with U.S. FDA to Discuss SHIELD I Phase 3 Results and Regulatory Pathway for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Meeting Scheduled for January 2023 PolyPid Recently Provided FDA with Currently Available Data from Completed SHIELD I Phase 3 Study in Advance of Meeting PETACH TIKVA, Israel, Dec. 12,...
December 09, 2022 16:01 ET | Source: PolyPid Ltd.

PolyPid Announces Receipt of Nasdaq Minimum Bid Price Notification

PETACH TIKVA, Israel, Dec. 09, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
November 29, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the First Triennial Meeting of the International Orthopaedic Trauma Association

PETACH TIKVA, Israel, Nov. 29, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
November 09, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Company Intends to Meet with U.S. and EU Regulatory Authorities to Discuss Data from SHIELD I Phase 3 Study and Regulatory Pathway for D-PLEX100 in First Quarter of 2023 Implemented a Cost Reduction...
October 26, 2022 07:00 ET | Source: PolyPid Ltd.

PolyPid to Report Third Quarter 2022 Financial Results and Operational Highlights on November 9, 2022

PETACH TIKVA, Israel, Oct. 26, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
October 20, 2022 07:09 ET | Source: PolyPid Ltd.

PolyPid Announces Cost Reduction Plan

Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 2023 PolyPid Intends to Discuss Regulatory Pathway for D-PLEX100 for Prevention of Surgical...